Background : Enoxaparin is an anticoagulant medication. Anticoagulation inhibits tumor cell–mediated release of angiogenic proteins and diminishes angiogenic response. Angiogenesis is an important event in various cancers such as breast cancer. Angiogenesis provide oxygen and nutrients to tumor cells and causes tumor progression. The aim of the present study was to evaluate the anti-angio...

drug utilization evaluation (due) is an effective program to identify variability in drug use and to support interventions that will improve patient outcomes. the appropriate use of enoxaparin, a low molecular weight heparin (lmwh), which is widely used as curative or preventive treatment of thromboembolic disorders was assessed in the study. a prospective due was carried out at masih daneshvar...

The aim of this study was evaluation of enoxaparin utilization in hospitalized patients who had received enoxaparin either for prophylaxis or for treatment of thromboembolic disorders. A total of  356 patients were included in this retrospective study and were analyzed for enoxaparin utilization in terms of prescription patterns, treatment strategy, dosing regimen, indications/contraindica...

the aim of this study was evaluation of enoxaparin utilization in hospitalized patients who had received enoxaparin either for prophylaxis or for treatment of thromboembolic disorders. a total of 356 patients were included in this retrospective study and were analyzed for enoxaparin utilization in terms of prescription patterns, treatment strategy, dosing regimen, indications/contraindications,...

OBJECTIVE To review enoxaparin treatment dosing, pharmacokinetics, and clinical outcomes data in patients with renal impairment and to examine the current two-tiered dosing regimen approved by the Food and Drug Administration (FDA). DATA SOURCES A literature search of PubMed (1990-2016) was performed using the search terms low-molecular-weight heparin, unfractionated heparin, bleeding, enoxap...

BACKGROUND ENTIRE-TIMI 23 evaluated enoxaparin with full-dose tenecteplase (TNK) and half-dose TNK plus abciximab. METHODS AND RESULTS Patients (n=483) with ST-elevation MI presenting <6 hours from symptom onset were randomized to full-dose TNK and either unfractionated heparin (UFH) (bolus 60 U/kg; infusion 12 U/kg per hour) or enoxaparin (1.0 mg/kg subcutaneously every 12 hours+/-initial 30...

BACKGROUND & AIMS We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular ca...

Objective: Heparin and enoxaparin possess anti-inflammatory properties. We compared the effects of these drugs on inflammatory biomarkers in patients with ST-segment Elevated Myocardial Infarction (STEMI). Method: Thirty four patients with STEMI randomly separated in two groups and received standard doses of heparin and enoxaparin. The serum concentration of Serum Amyloid A (SAA), C-Reactive Pr...